Welcome to our dedicated page for Cingulate SEC filings (Ticker: CING), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cingulate Inc. filings document a clinical-stage biopharmaceutical issuer developing Precision Timed Release™ drug-delivery products, including CTx-1301 for ADHD, alongside its common stock and warrants listed on Nasdaq. Periodic and current reports furnish operating results, business updates, patent notices, FDA-related program disclosures and research-and-development spending context.
The filing record also covers capital-structure actions such as private placements, preferred stock, warrants, unregistered equity issuances, debt exchanges and at-the-market offering agreements. Proxy and 8-K disclosures address shareholder voting matters, Nasdaq rule compliance, board committee composition, officer appointments, employment agreements and other governance events.
Cingulate Inc. reported a wider Q3 2025 net loss and highlighted liquidity needs as it advances its lead ADHD candidate. The company posted a net loss of $7,341,062 for the quarter, driven by higher research and development $2,848,544 and general and administrative $3,147,291 expenses. Cash and cash equivalents were $6,118,710 as of September 30, 2025.
Stockholders’ equity stood at $3,473,686, with total liabilities of $7,045,206. Operating cash outflow for the first nine months was $13,647,893. Subsequent to quarter end, the company raised debt proceeds of $6,000,000 under a new Avondale note at 9% and continued share sales under its Lincoln Park and ATM programs. Management states cash is expected to fund operations into the second quarter of 2026 and estimates it will need approximately $9,000,000 of additional capital to support commercialization efforts through the PDUFA target action date.
The FDA accepted the NDA for CTx‑1301 with a PDUFA target action date of May 31, 2026. Shares outstanding were 6,757,070 as of November 11, 2025.
Cingulate Inc. (CING) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025 and a business update. The materials were provided under Item 2.02 and are deemed furnished, not filed, which limits liability under Section 18 of the Exchange Act. The press release is included as Exhibit 99.1; the cover page Inline XBRL data file is listed as Exhibit 104.
Cingulate Inc. (CING) reported an insider equity grant. On 09/30/2025, EVP and CSO Raul Silva received a stock option covering 7,334 shares of common stock at an exercise price of $3.92, expiring 09/30/2035. The filing lists transaction code “A,” indicating an award. The option was granted pursuant to Dr. Silva’s Employment Agreement, as amended, and is held directly. Following the grant, 7,334 derivative securities were beneficially owned.
Cingulate Inc. (CING) reported a Form 4 showing its Chief Commercial Officer received a stock option grant to purchase 30,000 shares at an exercise price of $3.8 on 11/03/2025.
The option expires on 11/03/2035 and vests 25% on the one-year anniversary of the grant date, with the remaining shares vesting in substantially equal monthly installments over the following 36 months. Following the grant, 30,000 derivative securities were beneficially owned, held directly.
Cingulate Inc. (CING) disclosed an initial beneficial ownership report on Form 3 for Bryan Downey, its Chief Commercial Officer. The event date is 11/03/2025. The filing states that no securities are beneficially owned by the reporting person at the time of this report. The form was filed by one reporting person and includes an Exhibit 24 power of attorney.
Cingulate Inc. (CING) entered a financing on November 7, 2025, issuing an unsecured promissory note to Avondale Capital for a $6,570,000 principal amount that carries a 9% annual interest rate and matures in 18 months. The note was sold at a $540,000 original issue discount, generating $6,000,000 in cash proceeds for working capital and general corporate purposes.
Beginning May 7, 2026, the lender may redeem portions of the note up to $660,000 per month. The company may defer up to two redemptions for 30 days each before receiving an FDA “complete response letter,” with each deferral increasing the outstanding balance by 1%. If the note remains outstanding 90 days after its effective date, a monitoring fee applies per a formula tied to the then-outstanding balance.
Subsidiaries provided guarantees. The agreement includes customary defaults; certain defaults permit increases to the outstanding balance by 15% (Major Trigger) or 5% (Minor Trigger), each up to three times, and default interest up to 22% per year. Covenants restrict variable-rate transactions, include a most-favored-nation feature on future debt, allow prepayment, and give the lender an option (with company consent) to reinvest up to $5,000,000 on the same terms.
Cingulate Inc. announced a regulatory milestone: the FDA has accepted for review the New Drug Application for CTx-1301 (dexmethylphenidate), the company’s lead candidate for treating ADHD in children and adults. The FDA assigned a PDUFA target action date of May 31, 2026, setting the timeline for a decision after the agency’s standard review process. This step moves CTx-1301 into formal evaluation but does not indicate approval.
Cingulate Inc. reported the results of a Special Meeting of Stockholders held on September 25, 2025. Stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance of more than 20% of the company’s issued and outstanding common stock under a purchase agreement with Lincoln Park Capital Fund, LLC. This approval gives the company the stockholder authorization it needs to use that agreement for future share issuances.
For this Issuance Proposal, 1,597,394 shares were voted in favor, 213,885 against, and 9,561 abstained. Stockholders also approved a proposal to adjourn the Special Meeting if additional time were needed to secure votes on the Issuance Proposal, with 1,795,696 shares for, 125,763 against, and 19,805 abstentions, though adjournment was ultimately not required.